Veracyte (VCYT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.54
- EPS estimate
- $0.43
- EPS surprise
- +26.20%
- Revenue surprise
- +3.96%
- Revenue
- $150.3M
- Revenue estimate
- $144.6M
- Reported
- Jul 30, 2026
Veracyte reported Q2 2026 results on July 30, 2026. EPS was $0.54, beating the $0.43 estimate by 26.20%. Revenue of $150.3 million topped the $144.6 million consensus by 3.96%. Against Q2 2025, EPS rose about 23% from $0.44 and revenue rose about 15% from $130.2 million. Both are table highs.
The table shows a move from losses to profits. Veracyte posted a loss in every quarter from Q3 2021 through Q1 2024, the deepest at $0.41 per share in Q3 2023. It has been profitable in each of the nine quarters since. Annual results went from losses of $0.50 per share in 2022 and $1.03 in 2023 to earnings of $0.30 in 2024 and $1.79 in 2025. Revenue grew every year, from $297 million in 2022 to $517 million in 2025, a rise of about 74%. Over the last 20 quarters, Veracyte beat the EPS estimate 16 times. The most recent miss was Q4 2024, at 47.04% below.
Veracyte reported Q3 results between November 2 and November 9 in each of the past five years. That points to early November 2026 for the next report. It will show whether the year-over-year growth in EPS and revenue continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $0.43 | $0.54 | +26.20% | $150.3M | SEC |
| Q1 2026 | May 5, 2026 | $0.33 | $0.52 | +55.27% | $139.1M | SEC |
| Q4 2025 | Feb 25, 2026 | $0.41 | $0.53 | +29.52% | $140.6M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.32 | $0.51 | +59.13% | $131.9M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.28 | $0.44 | +57.65% | $130.2M | SEC |
| Q1 2025 | May 7, 2025 | $0.12 | $0.31 | +151.83% | $114.5M | SEC |
| Q4 2024 | Feb 24, 2025 | $0.11 | $0.06 | −47.04% | $118.6M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.03 | $0.19 | +486.42% | $115.9M | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.02 | $0.07 | +526.83% | $114.4M | SEC |
| Q1 2024 | May 7, 2024 | −$0.16 | −$0.02 | +87.42% | $96.8M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.10 | −$0.39 | −288.45% | $98.2M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.15 | −$0.41 | −179.86% | $90.1M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.15 | −$0.12 | +21.26% | $90.3M | SEC |
| Q1 2023 | May 4, 2023 | −$0.13 | −$0.11 | +18.22% | $82.4M | SEC |
| Q4 2022 | Feb 22, 2023 | −$0.15 | −$0.05 | +66.91% | $80.3M | SEC |
| Q3 2022 | Nov 2, 2022 | −$0.26 | −$0.12 | +53.54% | $75.6M | SEC |
| Q2 2022 | Aug 2, 2022 | −$0.22 | −$0.13 | +41.68% | $72.9M | SEC |
| Q1 2022 | May 3, 2022 | −$0.23 | −$0.20 | +13.72% | $67.8M | SEC |
| Q4 2021 | Feb 28, 2022 | −$0.16 | −$0.15 | +6.60% | $67.3M | SEC |
| Q3 2021 | Nov 9, 2021 | −$0.17 | −$0.20 | −17.65% | $60.4M | SEC |
Quarterly revenue
Frequently asked questions
When did Veracyte (VCYT) last report earnings?
Veracyte last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did VCYT beat earnings estimates?
Yes. Veracyte reported EPS of $0.54 for Q2 2026 against a $0.43 estimate — a 26.20% beat.
How much revenue did VCYT report last quarter?
Veracyte reported $150.3M in revenue for Q2 2026, against a consensus estimate of $144.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.